FDA grants priority review for Sanofi’s venglustat NDA
If approved, venglustat would be the first treatment in the US to address the neurological symptoms of GD3, which currently have no targeted therapies. The decision is anticipated
The collaboration aims to accelerate hit identification for these companies through a fee-for-success approach. It will combine OpenBench’s AI-based discovery platform with Concept Life Sciences’ expertise in medicinal